O.T.-skin cancer cure?

For all you crusty old, sun-bleached beach bums, I just got advert in mail from a company I buy hard to get supplements from. They are pretty reputable to my mind. Form you own conclusions but looks interesting to me:




Mail: IAS, IAS House, Les Autelets, Sark GY9 0SF, Great Britain Phone: 1-866-800-4677 (free phone from USA). Outside of USA please call +44 (0) 207 117 0107 otherwise please call +44 (0) 208 181 6105 Fax: +44 (0) 208 181 6106 E-mail: Website: www.antiaging-systems.com

The treatment of choice for non-melanoma skin cancers

By Bill E. Cham, Ph.D.

The laws of nature may be considered as; “the forces and processes that produce and control all the phenomena of the material world.”

The sun is a major force in nature and is essential for life on earth, unfortunately the sun also produces some unwanted side-effects for humans.

It is fashionable to have a suntan and people feel that exposing their skin to the sun is a healthy, pleasant thing to do. However, the sun also has a “dark side” in that, the ultraviolet part of the electromagnetic spectrum produced by the sun as light, in particular U.V.-B (290-320nm), is responsible for producing long-term solar skin damage (keratosis) and skin cancers. In fact, skin cancers are the most common malignancy in humans.

Curaderm-BEC5, is a topical cream preparation of a mixture of the glycoalkaloids solasodine glycosides (BEC). BECs are present in some solanaceous plants, including edible plants such as Solanum melongena (otherwise known as eggplant or aubergine). Now, BEC is available to the public for the treatment of cutaneous solar keratosis, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

This communication gives us some insight how, on the one hand, nature through one of its major forces- sun light, is causing increasingly higher incidences of human skin cancers but, on the other hand, nature, also with the involvement of sunlight and plants has supplied the solution on how to eradicate these skin cancers.

The etiologies of keratosis, BCC and SCC, their currently available treatments, and the particular attributes of Curaderm-BEC5 within these concepts of pathogenesis and therapeutics, are presented in this article.


An overgrowth of the epidermis forms a scaly layer on the skin. The start of this lesion is usually a small patch of dilated capillaries several millimetres in diameter. Then a dry, rough, adherent yellow or dirty brown scale forms, which may bleed if picked off. It may eventually become thick and horny, with a sharp, clear division between the keratosis and normal skin. Solar keratoses occasionally regress if sun exposure is stopped before they become too established. Although non-malignant, they are potentially malignant and can develop into cancer.

Basal Cell Carcinoma (BCC)

A BCC is a malignant tumour that rarely spreads to distant sites (metastasises). It starts in the basal layer of cells, between the basement membrane and the subsequent layer of cells and grows upwards from these. It consists of immature cells and has an organized complex of supportive tissue around it. The primary cause of BCC is sunlight exposed onto sensitive skin. Contributory causes are radiation damage, exposure to arsenic, burn scars and vaccination marks. BCCs are the most common malignant skin tumours in humans; they do not spread by metastases, but they erode tissue, and if not treated may eventually kill. BCCs may appear in a variety of guises and on first appearance, they are commonly small, rounded lumps with a pearly edge, and a thin surface covering with a few superficial transparent blood vessels. BCCs may also appear as ulcers, or as bleeding or non-healing lesions. Occasionally they appear as flat diffuse crusting or scaling red lesions. BCC tumours usually grow slowly but in a relentless manner. They then ulcerate and the ulcer will follow the spreading tumour, causing further damage, (for this reason they are also known as rodent ulcers).

Squamous Cell Carcinoma (SCC)

An SCC is a malignant tumour arising from the cells above the basal layer of the epidermis (prickle layer), usually after many years of exposure to sunlight. The cells in the prickle layer are maturing towards keratin formation and the cancer occurs when they accelerate in growth and breakthrough the basement membrane into the dermis. Although sunlight is the most common cause of SCC, any cancer-producing substance (carcinogen) may initiate its development. SCCs often arise from precancerous conditions such as solar keratoses. SCCs may also develop from skin ulcers, scar tissues, and x-ray damaged tissues, if this occurs then the chance of metastasis increases to approximately 20%. In addition, some 40% of transplant patients who are on immunosuppressive drugs develop SCCs within 5-years post-transplantation. This skin cancer is a serious problem and is potentially deadly. The first sign of an SCC is usually a thickening, with the lesion feeling firm, and the limits are not discrete. In the early stages there may be a crust that may later shed to show an ulcer. It may also form as a crack (fissure) or a small ulcer on the lip, which fails to heal and bleeds recurrently. The SCC may metastasise with an incidence of generally less than 5%.

Old Established Treatments


There are various surgical techniques available to treat skin cancer in its various forms. Surgical excision of a tumour has the advantage, that if done correctly, removes the affected area virtually completely. This treatment is extensive, requires anaesthesia and depending on the tumour, may require skin grafting with its accompanying cosmetic limitations. The risks of surgical intervention are well known and excision of BCCs or SCCs from the facial area often involves reconstructive surgery, which can be both time consuming and costly.


Radiotherapy, moreso prior to the 1950’s than now, has been used to treat most skin cancers. The disadvantage of this mode of treatment is the resulting scar tissue which may be depressed, depigmented and may also undergo degenerative and malignant changes at a later date.


Dermatological treatment consists of curettage and diathermy/ cauterisation, cryotherapy, chemosurgery and chemotherapy, and is generally used for superficial skin cancers. With curettage and diathermy, the tumour is scraped out and the bleeding stopped by cauterisation, (application of heat) by an electric current (diathermy). Cryotherapy, possibly the most widely used method, involves an intensely cold probe, cooled by liquid nitrogen, which is applied to the lesion. When the lesion thaws, there is pain in the treated area, followed by blister formation. Chemosurgery involves chemical fixation of the lesion and the fixed tissue is shaved off in layers. Chemotherapy with 5-fluorouracil (5-FU), which is an anti-metabolite and inhibits RNA and protein syntheses leading to cell death, is used to treat superficial lesions, but it is not specific for cancer cells. 5-FU is supplied as an ointment and requires considerable care in its application under medical supervision.

All of the above methods (surgery, radiotherapy and dermatogical) have their own individual limitations. However, the limitations common to all of these methods are:

  1. Formation of scar tissue.

  2. Lack of normal tissue regrowth.

  3. Limited access to the lesion if it is deep within the skin.

  4. A high rate of recurrence.

  5. Cosmetic end result.

New Specific Treatments

It is now well established that specific glycoalkaloids from the Solanum family have anticancer properties. The specific glycoalkaloids consist of BEC, which is a standardised mixture of triglycosides, solasonine and solamargine and their corresponding di- and mono-glycosides (1-12). All the glycosides contain the same aglycone, (the alkaloid without a sugar molecule)- solasodine.

Solasodine on its own does not have anticancer properties, however the mono-, di- and triglycosides do have anticancer properties. These glycosides contain a plant sugar rhamnose, which is not usually found in mammalian species. Specific endogenous lectins (EELS), which are specific receptors for the sugar part of the glycoalkaloids and are present in the plasma membranes of susceptible cancer cells but not normal cells recognize and bind the sugar rhamnose of the BEC glycoalkaloids. BEC subsequently enters the cancer cell and causes cell death by destroying the lysosome (6, 13-17).

BEC has been shown to have antineoplastic activity in cell culture, animals and in humans (1, 3-12). Currently Phase II studies with BEC are being carried out on terminal internal tumours in man. With these studies BEC in being administered intravenously (18).

Precursor of Curaderm-BEC5

A cream formulation of BEC in concentrations of 10% was well tolerated in an open tolerance and dose-finding Phase I and II studies in healthy volunteers and in patients with actinic keratosis, BCC and SCC (3). Application of the cream in this study resulted in swelling of the BCC and SCC lesions, with erythema (reddening) of the surrounding skin, then ulceration in about 2 days, followed over the next weeks by healing with healthy new cell growth. The only reported adverse events were mild itching and burning sensations at the site of the lesions in a few patients.


In another open study with 72 patients, their treatment with a cream formulation of BEC 0.005% called Curaderm-BEC5, resulted in the regression of all treated lesions (56 actinic keratoses, 39 BCCs and 29 SCCs), with 100% healed after 1 to 13 weeks of treatment (9). There were no lasting therapeutic effects in the 14 patients who received placebo.

It is important to note that Curaderm-BEC5 contained extremely low concentrations of BEC (0.005%). One tube of Curaderm containing 20g of cream formulation contained the equivalent of BEC as 5g of eggplant fruit (19). However, for BEC to be effective it must first be purified from its source by a specific process. Unlike other extracts used for therapeutic effects, in which the active ingredients have to be concentrated, with Curaderm-BEC5 the active ingredients in the plant material have to be diluted to still obtain the anticancer effects. In other words, the active glycoalkaloid ingredients are extremely safe as Curaderm-BEC5 contains less glycoalkaloid than the edible eggplant fruit!

Curaderm-BEC5 is applied at least twice daily to the skin and may be applied much more frequently if rapid regression of the tumour is required. Some patients apply the Curaderm-BEC5 cream up to 10 times daily. The cosmetic results after using Curaderm BEC5 are very impressive and over 80,000 patients have now used Curaderm-BEC5 successfully.

British clinical trials with Curaderm-BEC5

Recently a double-blind, vehicle-controlled (placebo), randomised, parallel group study of 94 patients was carried out to assess the efficacy and safety of Curaderm-BEC5 in the treatment of patients with BCC. This was a multi-centre Phase III study involving 10 centres in the United Kingdom.

The centres were as follows:

  • University of Wales College of Medicine.

  • Leicester Royal Infirmary.

  • The Royal London Hospital.

  • St. Mary’s Hospital.

  • St. Thomas’ Hospital.

  • Royal Free Hospital.

  • Singleton Hospital.

  • Royal Liverpool Hospital.

  • Derriford Hospital.

  • Hope Hospital.

The objectives of the study were to evaluate the efficacy and safety of Curaderm-BEC5 in the treatment of BCCs. The primary endpoint was defined as the complete healing of the index lesions, as confirmed by the absence of tumour- determined by clinical and histological examination after 8 weeks of twice daily treatments with Curaderm-BEC5 or placebo. The secondary endpoints were cosmetic evaluation, physician’s global evaluation of response to treatment, assessment of local irritation, reduction in size of the lesion and assessment of the frequency, nature and severity of adverse events.

The success rate (complete remission of skin cancers) of the Curaderm-BEC5 cream was 78% within 8-weeks. Longer than the 8 weeks duration therapy with Curaderm-BEC would have resulted in even higher success rates. These results were comparable to those previously obtained and published (4, 5, 13, 14). Not only was it shown that Curaderm-BEC5 was effective in treating superficial BCC, but in a subsequent open study trial comprising 41 patients (carried out at the Dermatology Department at the Royal London Hospital), it was also shown that Curaderm-BEC5 was effective on morpheoic BCC lesions, which are a type of invasive BCC.

The clinical trial experience has shown that Curaderm-BEC5 is safe. Only local skin irritation, some pain and erythema (reddening) occurred during treatment. Success was defined as zero presence of BCC after histological (microscopic) examination of samples, removed from the lesion sites by punch biopsy.

The conclusion of the dermatologists at the Royal London Hospital is that; “Curaderm-BEC5 is a topical preparation, which is safe and effective and an ideal therapy for outpatient treatment.” They stated further that; “Curaderm-BEC5 is a much-needed alternative to surgery for BCC. This is the most common cancer in Caucasians worldwide and the prevalence continues to increase with an increasing ageing population.” The final conclusion of these investigations was that; “Curaderm-BEC5 is a cost effective treatment for both primary and secondary skin cancer care.”

These Phase III and open studies confirm the previously published articles that; Curaderm-BEC5 is the method of choice for treating non-melanoma skin cancers.

Over 7,000 of the commonly prescribed drugs in the western world are derived from plants. Indeed, the plant kingdom has supplied us with some excellent drugs. Pain sufferers appreciate the relief provided by morphine. Victims of congestive heart failure appreciate the life-saving role of digitoxin or digoxin. Migraine patients experience the dramatic relief effected by ergotamine. Children with leukaemia have recognized the improvement of their condition by treatment with vincristine.

Importantly, in addition, the natural plant drugs have served as useful prototypes for even better medicines. Synthetic chemists have been able to convert morphine to hydro-morphone, lysergic acid to methylsergide, cocaine to procaine, physostigmine to neostigmine and even salicin to aspirin.

The fact that BEC shows such tremendous promise for treating internal cancers and the fact that Curaderm-BEC5 is now regarded as the method of choice for treating skin cancers lead us to conclude that Curaderm-BEC5 is a primary candidate to be added to the acceptable list of commonly prescribed drugs. Whether synthetic chemists will be able to classify BEC as a useful prototype for terminal internal cancers still remains to be seen.


  • The naturally occurring glycoalkaloids solasodine glycosides (BEC) have anticancer activity in cell culture, animals and in humans. Specific endogenous lectins which are present in the plasma membranes of cancer cells recognize and bind the sugar moiety of BEC. BEC is subsequently internalised and causes cell death by destroying the lysosome. This mode of action is very different than with other anticancer drugs (which are non-specific, destroying normal cells as well) and work on the nuclear contents such as the DNA or RNA of cells.

  • Independent centres show that Curaderm-BEC5 is virtually 100% effective for treating skin cancers if the lesions are treated for long enough.

  • The cosmetic result of skin cancer treatment with Curaderm-BEC5 is excellent.

  • Lesions treated appropriately with Curaderm-BEC5 result in no recurrence.

  • The amount of BEC in Curaderm is very small. One average-sized egg plant fruit (300g) contains the same amount of BEC as 60 tubes of Curaderm! Thus, Curaderm-BEC is safe as shown by the many published studies.

  • Curaderm-BEC5 is an ideal therapy for skin cancers.


  1. Cham BE, Gilliver M and Wilson L. Antitumour effects of glycoalkaloids isolated from Solanum sodomaeum. Planta Medica 1987; 53: 34-36.

  2. Cham BE and Wilson L. HPLC of glycoalkaloids from Solanum sodomaeum. Planta Medica 1987; 53: 59-62.

  3. Cham BE and Meares HM. Glycoalkaloids from Solanum sodomaeum are effective in the treatment of skin cancers in man. Cancer Letters 1987; 36: 111-118.

  4. Cham BE. Monograph on BEC. Drugs of the Future 1988; 13: 714-716.

  5. Cham BE and Daunter B. Curaderm (anti-neoplastic) launched in Australia. Drug News Perspectives 1989; 2: 112.

  6. Daunter B and Cham BE. Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells. Cancer Letters 1990; 55: 209-220.

  7. Cham BE and Daunter B. Solasodine glycosides. Selective cytotoxicity for cancer cells and inhibition of cytotoxicity by rhamnose in mice with Sarcoma 180 activity. Cancer Letters 1990; 55: 221-225.

  8. Cham BE and Daunter B. Topical treatment of pre-malignant and malignant skin cancers with Curaderm. Drugs of Today 1990; 26: 55-58.

  9. Cham BE, Daunter B, Evans RA. Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides. Cancer Letters 1991; 59: 183-192.

  10. Cham BE. Solasodine glycosides: a new modality for cancer. In: Walker, MS, ed. Proceedings of the third Oceania Symposium on complementary medicine. Queensland: Bio Concepts Publishing 1992; 30-36.

  11. Cham BE. The efficacy and mode of action of solasodine glycosides (BEC) on cancer cells. In: Walker MS, ed. Proceedings of the fourth Oceania Symposium on complimentary medicine. Queensland: Bio Concepts Publishing 1993; 41-51.

  12. Cham BE. Solasodine glycosides as anti-cancer agents: Pre-clinical and clinical studies. Asia Pacific Journal of Pharmacology 1994; 9: 113-118.

  13. Chang LC, Tsai TR, Wang JJ, Lin CN and Kuo KW. The rhamnose moiety of solamargine plays a crucial role in triggering cell death by aptosis. Biochemistry Biophysics Research Communication 1998; 242: 21-25.

  14. Hsu SH, Tsai TR, Lin CN, Yen MH and Kuo KW. Solamargine purified from Solanum incanum Chinese herb triggers gene expression of human TNFR1 which may lead to cell aptosis. Biochemistry Biophysics Research Communication 1996; 229: 1-5.

  15. Kuo KW, Hsu SH, Li YP, Lin WL, Chang LC, Lin CC, Lin CN and Sheu HM. Anticancer activity evaluation of the Solanum glycoalkaloid solamargine. Triggering aptosis in human hepatoma cells. Biochemistry Pharmacology 2000; 60: 1865-1973.

  16. Nakamura T, Komori C, Lee Y, Hashimoto F, Yahara S, Nohara T and Ejina A. Cytotoxic activities of Solanum steroidal glycosides. Biology Biopharmacy Bulletins 1996; 19: 564-566.

  17. Roddick JG, Weissenberg M and Leonard AL. Membrane disruption and enzyme inhibition of naturally-occurring and modified chaco-triose-containing Solanum steroidal glycoalkaloids. Phytochemistry 2001; 56: 603-610.

  18. Solbec Pharamaceuticals Limited, Australia. www.solbec.com.au

  19. Jones PG and Fenwick GR. The glycoalkaloid content of some edible Solanaceous fruits and potato products. Journal of Science and Food Agriculture 1981; 32: 419-421.


Ineresting, yes. The references provided, institutions involved and claimed results are impressive. It may very well be something worth looking into.

One issue I would bring up is that correctly diagnosing any type of lesion is not generally a “do-it-yourself” process. I.E. how do you know that spot on your ear is a NON-melanoma type of skin cancer, or any type of cancer at all?

I’m not a MD but have worked with enough of them to know that guessing is a dangerous game in the field of cancer. Even a board certified dermatologist would be reluctant to diagnose that spot on your ear without a biopsy and microscopic identification of the cells. Even then, shit can happen.

If it IS a melanoma (and hopefully the pathologist got it right), prompt surgical treatment may be the one thing that saves your life.

Impressive , too impressive? Says 80,000 Australians cured of non-melanomia skin cancer, was over the counter- now by prescription. I checked Australian Prescription Products Guide - no such drug available, neither curaderm or bec5. Checked with Australian Internet Pharmacy - no such drug. Checked Canadian and British Pharmacy sites - no such drug. Googled both names - only references for Curaderm lead to websites selling it - NO medical or pharmacological references. Checked New Zealand Dermatological Society site (dermnetnz.org- an excellent up to date site for info on skin cancer) no mention of curaderm among the many listed treatments including efudex ,metvix and Immoquodil. – I smell a rat! To me this is serious stuff as I have multiple skin cancers and seeing a treatment advertised for $ 125 for 20 mls. that claims 100% cure, with nothing to support it except their unsubstantiated claims pisses me off. I am aware that our FDA is often criticized for being slow in approving new drugs, and that people often look overseas as needed. I would just suggest that you look for the real thing. My belief at this time is that Curaderm is too good to be true.

google cansema black salve. It works. I have used it many times. If site you apply it to is non-cacerous tissue, it won’t react.

Quotes are from the advertising posted…


All of the above methods (surgery, radiotherapy and dermatogical) have their own individual limitations. However, the limitations common to all of these methods are:

  1. Formation of scar tissue.

  2. Lack of normal tissue regrowth.

  3. Limited access to the lesion if it is deep within the skin.

  4. A high rate of recurrence.

  5. Cosmetic end result.

100% BS ans deceptive advertising…and to be real nit-picky NONE of those are “limitations”…they probably should have had someone with an English degree translate.



There you get it straight from that horses mouth…their own advert.

I’m not saying this stuff can’t work or something like it won’t come along or it doesn’t have it’s own place right now, but you have to be out of your mind to avoid modern medical treatments in favor of this totally unproven routine. I would certainly try it if I was having continual problems and planning on 6 months in BF Egypt without access to medical care, and maybe as a supplement, but with halfway decent regular medical care these particular skin cancers can be treated easily. Most when caught early are simply burned or frozen off and you don’t even have to miss a day in the water. If it’s deep enough to require surgery that usually is in-office work - you usually feel less pain than the easier ones.

For what its worth I sent info to a friend who is very knowledgable about the alt.med world and he wrote back

There are various salves that often contain bloodroot and/ zinc chloride. Sometimes called black salve or Indian ointment Basically, the salve seems to trigger a strong, even violent immune reaction/inflammatory rsponse to cancer. A person with no cancer can smear the stuff over large body areas with no reaction. But if there is morbid cancerous tissue, even below the surface tissue, a lesion forms which last several months or more. Ugly and mildy painful, but not debilitating. Gradually, the morbid cancerous matter migrates to the surface with the exusions and falls off with the scab. Minimal or no scarring results, and the cancer is generally vanquished. With large tumors, the ordeal can be pretty exhausting, though safer than surgery. The lesions can freak people out if they are not prepared for what to expect.

This an old folk remedy for cancer going back thousands of years. It was even used by the ancient Greeks.Various botanicals can do the job, depending on what is available locally in the culture.

I have a friend who use something called “compound X” on her face and it worked but she said it was very painful and scary for about 15 days. And she is one tough cookie! A real pirate when it comes to self-care.

Also just got email back from another friend who used a “black salve” on his skin cancer:

I used the Black Salve from Dr Christoper or Natures Way not quite as

potent but did scar…much better than surgery and cost me $20.

Incoming for Dr. Strange…

I want to seize the opportunity to thank Dr. Strange for the BEC5 reference.

I’m 60, grew up bodysurfing, boating, skiing, surfing ('62), ocean lifeguarding within walking distance of the water. I’ve incurred countless severe sunburns to my Teutonic light skinned, haired, eyed body. I paid the first installment for my play at 54 with Moh’s surgery on a basal cell carcinoma, center forehead…my “dueling scar”.

In July '07 I was biopsy diagnosed with a BCC on my nose tip, and a squamous cell carcinoma on right chest. Approx. sizes 1-2 mm diameter, and 5x15 mm respectively. Anticipating the results, I began research on skin cancer on Sway’s before the biopsy returns confirmation and found Dr. Strange’s post. I continued the inquiry via Altavista .com, reference BEC5. Clinical trials and research appear solid.

I was prepared for my treatment consult with the Dermatologist and the recommended surgery as sole solution. Told in an optimistic tone that the BCC would result in but “minimal disfigurement” to my nose, I declined, having grown accustomed to my face and its distinguished good looks. Asked about BEC5 the Doc’s mouth said “no” as her body language screamed “yes” before she quickly excused herself. Her Nurse Practioner was, however, very interested. Between then and now I’ve discussed BEC5 with several affected friends and coworkers asking that they discuss it with their Docs. Results to date: 2 are unaware, 1 unaware and dismissive, 1 has heard of it but not familiar enough to comment. I’ll refrain from speculation on the disinterest, if you do the legwork you’ll encounter a probable motivation.

I’ve just completed my third week of self-treatment with it. Progress is as described in text and pictorially on the numerous sites. Healing is around 90% complete.

Disclaimer: my experience is anecdotal only. I do not recommend that anyone follow my lead in acting as your own physician lest you discover you have a misguided fool for a patient. I do encourage anyone wrestling with this scourge to invest the time necessary for adequate research. I’d also request that inquiries be made to your Dermatologists concerning BEC5 and that the input be posted here. I’ll update on any significant developments.

I wish it were a publically traded company.

Cool. It’s been a struggle for pharmacist finding the exact cure for this disease. Well, they should try combining all aspect and try considering some points. We’ll never know what are the results are.




I asked my dermatologist about this stuff and she said don't do it! There is a product on the market that can be used on Basal cell carcinomas called Aldara that has proven to be effective on some patients. A friend of mine had an adverse reaction to it that was almost mis-diagnosed as Hodgkins because of swelling in her lymph nodes in her neck! However, the treatment was successful and the lymph swelling went away.

My dermatologist has prescribed a topical cream called Efudex on two occasions that actually does attack pre-cancerous cells on the face and neck. It attacks pre-cancers and leaves normal skin cells alone and anything that looks suspicious after treatment is biopsied.  It's not prescribed on other areas like arms and back and I've tried it on my scalp with no results. What this does is saves you from biopsies and excissions later on. Probably not 100% effective, but it beats getting pre-cancers frozen or leaving them alone until they become a basal cell or squamous cell carcinoma and having mohs surgery done on your nose and lip (been there, done that!).

Bottom line, if you've had skin cancers or pre-cancers or you have a family history of skin cancers, don't ignore the warning signs.

As for me, I had a scab on my lower lip that wouldn't heal, and at my mom's insistence, went to my dermatolgist and had it biopsied. Turned out to be a squamous cell carcinoma, 5 mohs surgeries and 8 hours later, I had a large portion of my lower lip removed. Amazingly, you could hardly tell after it was all healed up. Sure looked like hell for the first couple of weeks though (not to mention trying to keep a bandaid on the lower lip). If I'd gone and gotten it checked early, the biopsy/ensuing surgery would have been much less invasive. Live and learn, I guess.